APA (7th ed.) Citation

Blazejak, C., Oymanns, M., Stranzenbach, R., Hillen, U., Mitteldorf, C., Nicolay, J. P., . . . Assaf, C. (2026). Brentuximab Vedotin in Advanced-Stage Mycosis Fungoides/Sézary Syndrome with Low CD30 Expression: Real-World Data from the German Cutaneous Lymphoma Network. Cancers, 18(1), 97. https://doi.org/10.3390/cancers18010097

Chicago Style (17th ed.) Citation

Blazejak, Christoph, et al. "Brentuximab Vedotin in Advanced-Stage Mycosis Fungoides/Sézary Syndrome with Low CD30 Expression: Real-World Data from the German Cutaneous Lymphoma Network." Cancers 18, no. 1 (2026): 97. https://doi.org/10.3390/cancers18010097.

MLA (9th ed.) Citation

Blazejak, Christoph, et al. "Brentuximab Vedotin in Advanced-Stage Mycosis Fungoides/Sézary Syndrome with Low CD30 Expression: Real-World Data from the German Cutaneous Lymphoma Network." Cancers, vol. 18, no. 1, 2026, p. 97, https://doi.org/10.3390/cancers18010097.